Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Open access
Schoenfeld, Jonathan D, Giobbie-Hurder, Anita, Ranasinghe, Srinika, Kao, Katrina Z, Lako, Ana, Tsuji, Junko, Liu, Yang, Brennick, Ryan C, Gentzler, Ryan D, Lee, Carrie, Hubbard, Joleen, Arnold, Susanne M, Abbruzzese, James L, Jabbour, Salma K, Uboha, Nataliya V, Stephans, Kevin L, Johnson, Jennifer M, Park, Haeseong, Villaruz, Liza C, Sharon, Elad, Streicher, Howard, Ahmed, Mansoor M, Lyon, Hayley, Cibuskis, Carrie, Lennon, Niall, Jhaveri, Aashna, Yang, Lin, Altreuter, Jennifer, Gunasti, Lauren, Weirather, Jason L, Mak, Raymond H, Awad, Mark M, Rodig, Scott J, Chen, Helen X, Wu, Catherine J, Monjazeb, Arta M, Hodi, F Stephen · 2022 · The Lancet Oncology

Abstract

Summary Background Patients with PD(L)-1 therapy resistant non-small cell lung cancer (NSCLC) have poor outcomes. Studies suggest radiotherapy may enhance anti-tumor immunity. Therefore, we investigated combined PD-L1 (durvalumab) and CTLA-4 inhibition (tremelimumab) alone or combined with radiation. Methods This multicentre, randomised, open-label phase 2 NCI Experimental Therapeutics Clinical Trials Network trial was conducted at 18 U.S. sites. Patients aged >=18 years with metastatic NSCLC, Eastern Cooperative Oncology Group performance status of 0 or 1, and progression during previous PD(L)-1 therapy were randomised (1:1:1) using a permuted block scheme, without stratification to durvalumab/tremelimumab (1500mg/75mg every 4 weeks, 4 cycles, intravenous) alone (noRT) or with low-dose (LDFRT) or hypofractionated (HFRT) radiotherapy followed by durvalumab until 52 weeks or progression. The primary endpoint was the rate of complete/partial response in patients who initiated study treatment. The trial is registered with ClinicalTrials.gov, NCT02888743, and is now complete. Findings 90 patients were randomised and 78 patients treated between 24 August 2017 and 29 March 2019. Median follow up was 12.4 months (IQR 7.8-15.1). There were no differences in response rates between the noRT arm (3 [11.5%] of 26, 90% CI 1.2-21.8) and the LDFRT (2 [7.7%] of 26, 0-16.3, p=0.64) or HFRT (3 [11.5%] of 26, 90% CI 1.2-21.8, p=0.99) arms. The most common grade 3-4 adverse event was dyspnea (2 [8%] of 26 NoRT, 3 [11%] LDFRT, and 3 [11%] HFRT). Serious adverse events occurred in 4 (15%, NoRT), 8 (31%, LDFRT) and 3 (12%, HFRT) patients. There was 1 grade-5 respiratory failure potentially related to therapy (LDFRT arm). Interpretation Radiation should not be used to increase response to PD-L1/CTLA-4 inhibition in PD(L)-1-resistant NSCLC patients. However, PD-L1/CTLA-4 therapy could be a treatment option for some patients. Future studies should refine predictive biomarkers in this setting. Funding: US National Institutes of Health, Dana-Farber Cancer Institute

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00658-6

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 240

Metadata

Authors
Schoenfeld, J. D., Giobbie-Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C., Hubbard, J., Arnold, S. M., Abbruzzese, J. L., Jabbour, S. K., Uboha, N. V., Stephans, K. L., Johnson, J. M., Park, H., Villaruz, L. C., Sharon, E., Streicher, H., Ahmed, M. M., Lyon, H., Cibuskis, C., Lennon, N., Jhaveri, A., Yang, L., Altreuter, J., Gunasti, L., Weirather, J. L., Mak, R. H., Awad, M. M., Rodig, S. J., Chen, H. X., Wu, C. J., Monjazeb, A. M., & Hodi, F. S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-02
Volume
23
Issue
2
Pages
279-291
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4206362366
Cited by
240
References
15
FWCI
19.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00658-6
The paper
Schoenfeld, J. D., Giobbie-Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C., Hubbard, J., Arnold, S. M., Abbruzzese, J. L., Jabbour, S. K., Uboha, N. V., Stephans, K. L., Johnson, J. M., Park, H., Villaruz, L. C., . . . Hodi, F. S. (2022). Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00658-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.